A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi; Masaya Hibino; Ryota Hase; Michiko Yamamoto; Yu Kasamatsu; Masahiro Hirose; Yoshikazu Mutoh; Yoshito Homma; Masaki Terada; Taku Ogawa; Fumihiro Kashizaki; Toshihiko Yokoyama; Hayato Koba; Hideki Kasahara; Kazuhisa Yokota; Hideaki Kato; Junichi Yoshida; Toshiyuki Kita; Yasuyuki Kato; Tadashi Kamio; Nobuhiro Kodama; Yujiro Uchida; Nobuhiro Ikeda; Masahiro Shinoda; Atsushi Nakagawa; Hiroki Nakatsumi; Tomoya Horiguchi; Mitsunaga Iwata; Akifumi Matsuyama; Sumi Banno; Takenao Koseki; Mayumi Teramachi; Masami Miyata; Shigeru Tajima; Takahiro Maeki; Eri Nakayama; Satoshi Taniguchi; Chang Kweng Lim; Masayuki Saijo; Takumi Imai; Hisako Yoshida; Daijiro Kabata; Ayumi Shintani; Yukio Yuzawa; Masashi Kondo

Antimicrobial Agents and Chemotherapy (2020) - Comments
doi: 10.1128/aac.01897-20 issn: 0066-4804 issn: 1098-6596 pubmed: 32958718

Yohei Doi, Masaya Hibino, Ryota Hase, Michiko Yamamoto, Yu Kasamatsu, Masahiro Hirose, Yoshikazu Mutoh, Yoshito Homma, Masaki Terada, Taku Ogawa, Fumihiro Kashizaki, Toshihiko Yokoyama, Hayato Koba, Hideki Kasahara, Kazuhisa Yokota, Hideaki Kato, Junichi Yoshida, Toshiyuki Kita, Yasuyuki Kato, Tadashi Kamio

Go to article
Go to preprint

American Society for Microbiology